Clinical trial NCT01270386 (phase 2, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: apatinib, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 and ≤ 70 years of age

          -  Histologically or cytologic confirmed advanced non-squamous and non-small cell lung
             cancer.

          -  At least one measurable lesion which has not received radiotherapy (larger than 10 mm
             in diameter by spiral CT scan)

          -  Have failed for 2 lines of chemotherapy including EGFR-TKI.

          -  ECOG performance scale 0 - 1.

          -  Life expectancy of more than 3 months.

          -  Duration from the last therapy is more than 6 weeks for nitroso or mitomycin

          -  More than 4 weeks after operation or radiotherapy

          -  More than 4 weeks for cytotoxic agents or tyrosine kinase inhibitors inhibitors

          -  Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L,
             platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.25×the upper
             limit of normal(ULN), and serum transaminase≤2.5×the ULN (If liver metastases, serum
             transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥
             50ml/min,

          -  signed and dated informed consent.Willingness and ability to comply with scheduled
             visits, treatment plans, laboratory tests, and other study procedure.

        Exclusion Criteria:

          -  Squamous cell carcinoma (including adenosquamous carcinoma, undifferentiated
             carcinoma); small cell lung cancer (including small cell and non-small cell mixed lung
             cancer)

          -  Pregnant or breastfeeding women

          -  Intercurrence with one of the following: hypertension, coronary artery disease,
             arrhythmia and heart failure

          -  Any factors that influence the usage of oral administration

          -  PT, APTT, TT, Fbg abnormal, Receiving the therapy of thrombolysis or anticoagulation.

          -  Within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ CTCAE
             class 2) or other parts' hemorrhage (≥ CTCAE class 3).

          -  Long-term untreated wounds or fractures.

          -  Within 6 months before the first treatment occurs artery / venous thromboembolic
             events, such as cerebral vascular accident (including transient ischemic attack), deep
             vein thrombosis and pulmonary embolism, etc.

          -  Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or
             its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5,
             with the purpose of prevention, the use of small doses of warfarin (1mg orally, once
             daily) or low-dose aspirin (between 80mg to 100mg daily) is allowed.

          -  Abuse of alcohol or drugs

          -  Less than 4 weeks from the last clinical trial

          -  Treatment with VEGFR, PDGFR, sSRC-TKI before.

          -  History of any second malignancies within 3 years except cured basal cell carcinoma of
             skin and carcinoma in-situ of uterine cervix.